ReviewNature reviews. Rheumatology2014
The safety of biologic therapies in RA-associated interstitial lung disease.
Review in Nature reviews. Rheumatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 83 citations in OpenAlex.
- Incidence of interstitial lung disease in seropositive rheumatoid arthritis patients receiving biologics, Janus kinase inhibitors, or methotrexate.Therapeutic advances in musculoskeletal disease · 2026Article
- Advanced therapies in US veterans with rheumatoid arthritis-associated interstitial lung disease: a retrospective, active-comparator, new-user, cohort study.The Lancet. Rheumatology · 2025Observational
- Patient-Centric Approach for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Older People.Drugs & aging · 2025Review
- Shared immunological pathways in rheumatoid arthritis-related interstitial lung disease.Frontiers in immunology · 2025Review
- Exploring pulmonary involvement in newly diagnosed rheumatoid arthritis, and psoriatic arthritis: a single center study.Rheumatology international · 2024Article
- Traditional Tibetan medicine: therapeutic potential in lung diseases.Frontiers in pharmacology · 2024Review
- Risk factors for interstitial lung disease in rheumatoid arthritis: a cohort study from the KOBIO registry.Therapeutic advances in musculoskeletal disease · 2024Article
- Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib.Journal of clinical medicine · 2023Review
- Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs.JAMA network open · 2023Article
- Unmet needs and perspectives in rheumatoid arthritis-associated interstitial lung disease: A critical review.Frontiers in medicine · 2023Review
- Article
- Review
- Interstitial Lung Disease in Rheumatoid Arthritis: A Practical Review.Frontiers in medicine · 2022Review
- Rheumatoid arthritis-associated interstitial lung disease: Current update on prevalence, risk factors, and pharmacologic treatment.Current treatment options in rheumatology · 2020Article
- Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows.Journal of clinical medicine · 2020Review
- Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study.Journal of clinical medicine · 2020Article
- Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?Respiratory medicine case reports · 2020Article
- Thoracic Manifestations of Rheumatoid Arthritis.Clinics in chest medicine · 2019Review
- Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?Current opinion in rheumatology · 2019Review
- [Pulmonary involvement in rheumatoid arthritis].Zeitschrift fur Rheumatologie · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Interstitial lung disease (ILD) is a common extra-articular manifestation associated with increased morbidity and mortality in patients with rheumatoid arthritis (RA). Early case reports of serious respiratory adverse events (SRAEs) following treatment with anti-TNF agents have led to concerns about biologic therapy in patients with RA-associated ILD (RA-ILD), and a tendency for biologic agents targeting factors other than TNF to be prescribed in such patients. At present, the appropriateness of such decisions is not clear. Given that the therapeutic goal for RA is remission, clinicians increasingly face the challenge of choosing the optimal biologic agent in patients with RA-ILD and uncontrolled joint disease. However, no evidence-based guidelines exist to guide physicians in deciding whether to commence biologic therapy in this setting, or in selecting which drug is most appropriate. Herein, we review the evidence for the comparative pulmonary safety of anti-TNF agents and non-TNF-targeting biologic agents in RA-ILD. In addition, we propose a framework for assessment of baseline disease severity to guide treatment decisions, and for monitoring during therapy. Because of substantial gaps in the available evidence, we also describe a research agenda aimed at obtaining data that will help inform future clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.